PharmaMar
Jazz and PharmaMar’s Zepzelca combo misses main goal in small cell lung cancer sub-population
December 3, 2020Research and Development PharmaMar, jazz pharma, trial failure
Jazz Pharma and PharmaMar have revealed that their jointly-developed therapy Zepzelca (lurbinectedin), when combined with doxorubicin, fell short of its …
FDA approval for Jazz and PharmaMar’s Zepzelca in metastatic small cell lung cancer
June 17, 2020Manufacturing and Production, Research and Development, Sales and Marketing Cancer, FDA, PharmaMar, Zepzelca, jazz pharma, lung cancer
The FDA has awarded approval to Jazz Pharma and PharmaMar for Zepzelca (lurbinectedin) as a treatment for metastatic small cell …
NICE gives final no to PharmaMar’s Yondelis
April 27, 2011Sales and Marketing NICE, PharmaMar, Yondelis, ovarian cancer
A lack of evidence and an unconvincing patient access scheme has seen PharmaMar fail to win NICE backing for its …
NICE rejects PharmaMar’s ovarian cancer drug Yondelis
March 14, 2011Sales and Marketing Cancer, NICE, PharmaMar, Trabectedin, Yondelis, ovarian cancer
NICE has rejected PharmaMar’s ovarian cancer drug in final draft guidance due to a lack of ‘robust’ data. Yondelis (trabectedin) …
NICE rejects Yondelis in ovarian cancer
June 21, 2010Sales and Marketing NICE, PharmaMar, Yondelis, ovarian cancer
New cancer treatment Yondelis has been rejected by NICE in a preliminary ruling on its use in relapsed ovarian cancer. …
Zeltia continue strong growth
February 26, 2010Sales and Marketing 2009 financials, PharmaMar, Yondelis, Zeltia
Consolidated revenues at Spanish biopharmaceutical company Zeltia increased by 17% to 123.4 million euros enabling it to halve operating losses. …
NICE approves Yondelis
February 24, 2010Sales and Marketing NICE, PharmaMar, Yondelis
Cancer drug Yondelis has been approved by NICE for use on the NHS, but only after the manufacturer offered to …
NICE approves Trabectedin
January 19, 2010Sales and Marketing NICE, PharmaMar, Trabectedin, soft tissue sarcoma
Patients with advanced soft tissue sarcoma could now benefit from PharmaMar’s new drug trabectedin, after the NICE granted its approval. …
